Ascendis Pharma A/S
ASND
$164.65
-$4.19-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 56.16% | 38.23% | 10.93% | -19.59% | 55.87% |
| Total Depreciation and Amortization | -11.69% | -6.85% | -6.59% | -0.31% | 12.93% |
| Total Amortization of Deferred Charges | -4.27% | -- | -- | -- | 14.61% |
| Total Other Non-Cash Items | -10.59% | -199.51% | 3,393.96% | 677.93% | 12.73% |
| Change in Net Operating Assets | -300.02% | 854.78% | 55.24% | -129.54% | -1,247.64% |
| Cash from Operations | -103.24% | 54.54% | 60.41% | 30.07% | 68.42% |
| Capital Expenditure | -758.70% | 51.67% | 23.84% | 81.44% | 101.75% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -99.47% | -100.16% | -100.00% | -96.48% | 132.37% |
| Cash from Investing | -105.72% | -102.29% | -98.72% | -96.56% | 979.32% |
| Total Debt Issued | 100.00% | -4.02% | -- | -- | -- |
| Total Debt Repaid | -7.75% | -7.41% | -12.04% | -8.49% | -53.74% |
| Issuance of Common Stock | 1,006.29% | 4,687.34% | 75.48% | 1,036.60% | -35.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -90,500.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 101.42% | 201.47% | -5.14% | 2,756.71% | -572.95% |
| Foreign Exchange rate Adjustments | 394.45% | -172.17% | 12.17% | 164.66% | 66.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.03% | 687.55% | 43.16% | -228.83% | 68.37% |
